Founder mutations characterise the mutation panorama in 200 Swedish index cases referred for Long QT syndrome genetic testing

BMC Cardiovascular Disorders

Anna Norberg¹  Annika Rydberg³  Steen M Jensen²  Ulla-Britt Diamant²  Björn-Anders Jonsson¹  Jenni Jonasson¹  Kristina Cederquist¹  Annika Winbo³  Ida Maria Boström¹  Eva-Lena Stattin¹ 

[1] Department of Medical Biosciences, Medical and Clinical Genetics, Umeå University, Umeå, Sweden;Heart Centre and Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden;Department of Clinical Sciences, Paediatrics, Umeå University, Umeå, Sweden

关键词: Variant of unknown significance;    Founder mutation;    Ion-channel;    Long QT syndrome;    Arrhythmia;   

Others  :  858029
DOI  :  10.1186/1471-2261-12-95

 received in 2012-06-28, accepted in 2012-10-10,  发布年份 2012

【 摘 要 】

Background

Long QT syndrome (LQTS) is an inherited arrhythmic disorder characterised by prolongation of the QT interval on ECG, presence of syncope and sudden death. The symptoms in LQTS patients are highly variable, and genotype influences the clinical course. This study aims to report the spectrum of LQTS mutations in a Swedish cohort.

Methods

Between March 2006 and October 2009, two hundred, unrelated index cases were referred to the Department of Clinical Genetics, Umeå University Hospital, Sweden, for LQTS genetic testing. We scanned five of the LQTS-susceptibility genes (KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2) for mutations by DHPLC and/or sequencing. We applied MLPA to detect large deletions or duplications in the KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 genes. Furthermore, the gene RYR2 was screened in 36 selected LQTS genotype-negative patients to detect cases with the clinically overlapping disease catecholaminergic polymorphic ventricular tachycardia (CPVT).

Results

In total, a disease-causing mutation was identified in 103 of the 200 (52%) index cases. Of these, altered exon copy numbers in the KCNH2 gene accounted for 2% of the mutations, whereas a RYR2 mutation accounted for 3% of the mutations. The genotype-positive cases stemmed from 64 distinct mutations, of which 28% were novel to this cohort. The majority of the distinct mutations were found in a single case (80%), whereas 20% of the mutations were observed more than once. Two founder mutations, KCNQ1 p.Y111C and KCNQ1 p.R518*, accounted for 25% of the genotype-positive index cases. Genetic cascade screening of 481 relatives to the 103 index cases with an identified mutation revealed 41% mutation carriers who were at risk of cardiac events such as syncope or sudden unexpected death.

Conclusion

In this cohort of Swedish index cases with suspected LQTS, a disease-causing mutation was identified in 52% of the referred patients. Copy number variations explained 2% of the mutations and 3 of 36 selected cases (8%) harboured a mutation in the RYR2 gene. The mutation panorama is characterised by founder mutations (25%), even so, this cohort increases the amount of known LQTS-associated mutations, as approximately one-third (28%) of the detected mutations were unique.

【 授权许可】

   
2012 Stattin et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Goldenberg I, Zareba W, Moss AJ: Long QT Syndrome. Curr Probl Cardiol 2008, 33(11):629-694.
• [2]Kramer DB, Zimetbaum PJ: Long-QT syndrome. Cardiol Rev 2011, 19(5):217-225.
• [3]Ackerman MJ: The long QT syndrome: ion channel diseases of the heart. Mayo Clin Proc 1998, 73(3):250-269.
• [4]Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, Vicentini A, Spazzolini C, Nastoli J, Bottelli G, et al.: Risk stratification in the long-QT syndrome. N Engl J Med 2003, 348(19):1866-1874.
• [5]Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, et al.: Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001, 103(1):89-95.
• [6]Wilde AA, Jongbloed RJ, Doevendans PA, Duren DR, Hauer RN, van Langen IM, van Tintelen JP, Smeets HJ, Meyer H, Geelen JL: Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1). J Am Coll Cardiol 1999, 33(2):327-332.
• [7]Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, DeSimone L, Coltorti F, Bloise R, Keegan R, et al.: Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002, 106(1):69-74.
• [8]Berge KE, Haugaa KH, Fruh A, Anfinsen OG, Gjesdal K, Siem G, Oyen N, Greve G, Carlsson A, Rognum TO, et al.: Molecular genetic analysis of long QT syndrome in Norway indicating a high prevalence of heterozygous mutation carriers. Scand J Clin Lab Invest 2008, 68(5):362-368.
• [9]Tester DJ, Kopplin LJ, Will ML, Ackerman MJ: Spectrum and prevalence of cardiac ryanodine receptor (RyR2) mutations in a cohort of unrelated patients referred explicitly for long QT syndrome genetic testing. Hear Rhythm 2005, 2(10):1099-1105.
• [10]Roden DM: Clinical practice. Long-QT syndrome. N Engl J Med 2008, 358(2):169-176.
• [11]Bokil NJ, Baisden JM, Radford DJ, Summers KM: Molecular genetics of long QT syndrome. Mol Genet Metab 2010, 101(1):1-8.
• [12]Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, Vincent GM, et al.: Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000, 102(10):1178-1185.
• [13]Tester DJ, Will ML, Haglund CM, Ackerman MJ: Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Hear Rhythm 2005, 2(5):507-517.
• [14]Kapplinger JD, Tester DJ, Alders M, Benito B, Berthet M, Brugada J, Brugada P, Fressart V, Guerchicoff A, Harris-Kerr C, et al.: An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Hear Rhythm 2010, 7(1):33-46.
• [15]Napolitano C, Priori SG, Schwartz PJ, Bloise R, Ronchetti E, Nastoli J, Bottelli G, Cerrone M, Leonardi S: Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA 2005, 294(23):2975-2980.
• [16]Tranebjaerg L, Bathen J, Tyson J, Bitner-Glindzicz M: Jervell and Lange-Nielsen syndrome: a Norwegian perspective. Am J Med Genet 1999, 89(3):137-146.
• [17]Fodstad H, Swan H, Laitinen P, Piippo K, Paavonen K, Viitasalo M, Toivonen L, Kontula K: Four potassium channel mutations account for 73% of the genetic spectrum underlying long-QT syndrome (LQTS) and provide evidence for a strong founder effect in Finland. Ann Med 2004, 36(Suppl 1):53-63.
• [18]Crotti L, Spazzolini C, Schwartz PJ, Shimizu W, Denjoy I, Schulze-Bahr E, Zaklyazminskaya EV, Swan H, Ackerman MJ, Moss AJ, et al.: The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. Circulation 2007, 116(21):2366-2375.
• [19]Itoh H, Shimizu W, Hayashi K, Yamagata K, Sakaguchi T, Ohno S, Makiyama T, Akao M, Ai T, Noda T, et al.: Long QT syndrome with compound mutations is associated with a more severe phenotype: a Japanese multicenter study. Hear Rhythm 2010, 7(10):1411-1418.
• [20]Kapa S, Tester DJ, Salisbury BA, Harris-Kerr C, Pungliya MS, Alders M, Wilde AA, Ackerman MJ: Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants. Circulation 2009, 120(18):1752-1760.
• [21]Antonarakis SE: Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat 1998, 11(1):1-3.
• [22]Kumar P, Henikoff S, Ng PC: Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009, 4(7):1073-1081.
• [23]Sunyaev S, Ramensky V, Koch I, Lathe W 3rd, Kondrashov AS, Bork P: Prediction of deleterious human alleles. Hum Mol Genet 2001, 10(6):591-597.
• [24]Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007, 28(6):622-629.
• [25]Benson DW, Wang DW, Dyment M, Knilans TK, Fish FA, Strieper MJ, Rhodes TH, George AL Jr: Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J Clin Invest 2003, 112(7):1019-1028.
• [26]Winbo A, Diamant UB, Rydberg A, Persson J, Jensen SM, Stattin EL: Origin of the Swedish long QT syndrome Y111C/KCNQ1 founder mutation. Hear Rhythm 2011, 8(4):541-547.
• [27]Jespersen T, Rasmussen HB, Grunnet M, Jensen HS, Angelo K, Dupuis DS, Vogel LK, Jorgensen NK, Klaerke DA, Olesen SP: Basolateral localisation of KCNQ1 potassium channels in MDCK cells: molecular identification of an N-terminal targeting motif. J Cell Sci 2004, 117(Pt 19):4517-4526.
• [28]Dahimene S, Alcolea S, Naud P, Jourdon P, Escande D, Brasseur R, Thomas A, Baro I, Merot J: The N-terminal juxtamembranous domain of KCNQ1 is critical for channel surface expression: implications in the Romano-Ward LQT1 syndrome. Circ Res 2006, 99(10):1076-1083.
• [29]Winbo A, Diamant UB, Stattin EL, Jensen SM, Rydberg A: Low incidence of sudden cardiac death in a Swedish Y111C type 1 long-QT syndrome population. Circ Cardiovasc Genet 2009, 2(6):558-564.
• [30]Amin AS, Giudicessi JR, Tijsen AJ, Spanjaart AM, Reckman YJ, Klemens CA, Tanck MW, Kapplinger JD, Hofman N, Sinner MF, et al.: Variants in the 3’ untranslated region of the KCNQ1-encoded Kv7.1 potassium channel modify disease severity in patients with type 1 long QT syndrome in an allele-specific manner. Eur Heart J 2012, 33(6):714-723.
• [31]Olsson M, Norgren N, Obayashi K, Plante-Bordeneuve V, Suhr OB, Cederquist K, Jonasson J: A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers. BMC Med Genet 2010, 11:130. BioMed Central Full Text
• [32]Wei J, Fish FA, Myerburg RJ, Roden DM, George AL Jr: Novel KCNQ1 mutations associated with recessive and dominant congenital long QT syndromes: evidence for variable hearing phenotype associated with R518X. Hum Mutat 2000, 15(4):387-388.
• [33]Larsen LA, Fosdal I, Andersen PS, Kanters JK, Vuust J, Wettrell G, Christiansen M: Recessive Romano-Ward syndrome associated with compound heterozygosity for two mutations in the KVLQT1 gene. Eur J Hum Genet 1999, 7(6):724-728.
• [34]Winbo A, Stattin EL, Diamant UB, Persson J, Jensen SM, Rydberg A: Prevalence, mutation spectrum, and cardiac phenotype of the Jervell and Lange-Nielsen syndrome in Sweden. Europace 2012. [Epub ahed of print]
• [35]Marjamaa A, Salomaa V, Newton-Cheh C, Porthan K, Reunanen A, Karanko H, Jula A, Lahermo P, Vaananen H, Toivonen L, et al.: High prevalence of four long QT syndrome founder mutations in the Finnish population. Ann Med 2009, 41(3):234-240.
• [36]Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, Hofman N, Bikker H, van Tintelen JP, Mannens MM, Wilde AA, Ackerman MJ: The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis. J Am Coll Cardiol 2009, 54(22):2065-2074.
• [37]Koopmann TT, Alders M, Jongbloed RJ, Guerrero S, Mannens MM, Wilde AA, Bezzina CR: Long QT syndrome caused by a large duplication in the KCNH2 (HERG) gene undetectable by current polymerase chain reaction-based exon-scanning methodologies. Hear Rhythm 2006, 3(1):52-55.
• [38]Eddy CA, MacCormick JM, Chung SK, Crawford JR, Love DR, Rees MI, Skinner JR, Shelling AN: Identification of large gene deletions and duplications in KCNQ1 and KCNH2 in patients with long QT syndrome. Hear Rhythm 2008, 5(9):1275-1281.
• [39]Barc J, Briec F, Schmitt S, Kyndt F, Le Cunff M, Baron E, Vieyres C, Sacher F, Redon R, Le Caignec C, et al.: Screening for copy number variation in genes associated with the long QT syndrome: clinical relevance. J Am Coll Cardiol 2011, 57(1):40-47.
• [40]Tester DJ, Benton AJ, Train L, Deal B, Baudhuin LM, Ackerman MJ: Prevalence and spectrum of large deletions or duplications in the major long QT syndrome-susceptibility genes and implications for long QT syndrome genetic testing. Am J Cardiol 2010, 106(8):1124-1128.
• [41]Imboden M, Swan H, Denjoy I, Van Langen IM, Latinen-Forsblom PJ, Napolitano C, Fressart V, Breithardt G, Berthet M, Priori S, et al.: Female predominance and transmission distortion in the long-QT syndrome. N Engl J Med 2006, 355(26):2744-2751.
• [42]Westenskow P, Splawski I, Timothy KW, Keating MT, Sanguinetti MC: Compound mutations: a common cause of severe long-QT syndrome. Circulation 2004, 109(15):1834-1841.
• [43]Refsgaard L, Holst AG, Sadjadieh G, Haunso S, Nielsen JB, Olesen MS: High prevalence of genetic variants previously associated with LQT syndrome in new exome data. Eur J Hum Genet 2012, 20:905-908.
• [44]Tester DJ, Valdivia C, Harris-Kerr C, Alders M, Salisbury BA, Wilde AA, Makielski JC, Ackerman MJ: Epidemiologic, molecular, and functional evidence suggest A572D-SCN5A should not be considered an independent LQT3-susceptibility mutation. Hear Rhythm 2010, 7(7):912-919.
• [45]Van Norstrand DW, Tester DJ, Ackerman MJ: Overrepresentation of the proarrhythmic, sudden death predisposing sodium channel polymorphism S1103Y in a population-based cohort of African-American sudden infant death syndrome. Hear Rhythm 2008, 5(5):712-715.